AFFIMED N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.49 USD | +9.15% |
|
+9.80% | -12.16% |
| 01/04 | Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating | MT |
| 01/04 | HC Wainwright Adjusts Affimed's Price Target to $10 From $50, Maintains Buy Rating | MT |
| Sales 2024 * | 5.39M 5.78M 482M | Sales 2025 * | 4.83M 5.18M 432M | Capitalization | 71.75M 76.92M 6.42B |
|---|---|---|---|---|---|
| Net income 2024 * | -88M -94.35M -7.87B | Net income 2025 * | -99M -106M -8.86B | EV / Sales 2024 * | 13.3 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 14.8 x |
| P/E ratio 2024 * |
-0.98
x | P/E ratio 2025 * |
-1.15
x | Employees | 76 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on Affimed N.V.
More recommendations
More press releases
| 1 day | +9.15% | ||
| 1 week | +9.80% | ||
| Current month | +3.58% | ||
| 1 month | -13.54% | ||
| 3 months | -1.96% | ||
| 6 months | +64.91% | ||
| Current year | -12.16% |
1 week
4.56
5.59
1 month
4.567.24
Current year
4.257.40
1 year
2.2411.10
3 years
2.24112.60
5 years
2.24117.40
10 years
2.24242.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 01/20/01 | |
Harry Welten
DFI | Director of Finance/CFO | 59 | 04/20/04 |
Wolfgang Fischer
COO | Chief Operating Officer | 60 | 13/17/13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ulrich Grau
BRD | Director/Board Member | 75 | 01/15/01 |
Thomas O. Hecht
CHM | Chairman | 73 | 01/07/01 |
Harry Welten
DFI | Director of Finance/CFO | 59 | 04/20/04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 5.49 | +9.15% | 102 331 |
| 26/24/26 | 5.03 | +3.07% | 48,580 |
| 25/24/25 | 4.88 | 0.00% | 71,155 |
| 24/24/24 | 4.88 | -8.79% | 65,594 |
| 23/24/23 | 5.35 | +7.00% | 22,001 |
Delayed Quote Nasdaq, April 30, 2024 at 01:30 am IST
More quotes
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Calendar
22/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.712
EUR
Average target price
20.83
EUR
Spread / Average Target
+342.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.16% | 76.59M | |
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- AFMD Stock
